KevinCompounds said:Orforglipron is the more interesting oral story because it is not a peptide at all.
I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.
Adding the numbers, since they settle part of this. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.
Dr.SportsMedIN said:I do not accept that the fasting window is a minor inconvenience.
Coming at Dr.SportsMedIN’s question from a different direction. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.
Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFollowing on from amy_econ_NJ — and this may be the naive question:
Whether the fasting requirement is as strict in practice as the label implies, and what people actually see when they get it wrong?
Closing the loop on my own question.
Follow-up: moving the tablet to the moment I wake, before anything else, was the whole fix. The dose never changed.